Results: Eighty-four patients with CTDs were enrolled, including 42 patients with rheumatoid arthritis (RA). The level of procalcitonin was evaluated in all patients, and the level of presepsin was in 48 patients. Thirty-six patients were classified in infection group; 38 patients in the CRP-positive non-infection group; and 10 patients in CRP-negative non-infection group. The level of presepsin was significant higher in infection group than CRP-positive non-infection group (693 +/-577 pg/mL vs. 250 +/-101 pg/mL, p<0.01) (Fig. 1) . Among the patients with RA, the level of presepsin was significant higher in infection group than non-infection group (809 +/-637 pg/mL vs. 233 +/-135 pg/mL, p<0.01). AUCs of procalcitonin (0.823) and presepsin (0.821) showed similar diagnostic value. The cut-off value of presepsin and procalcitonin were 265 pg/mL and 0.16 ng/mL, respectively (sensitivity: 78.3% and 82.6%, specificity: 76.0% and 76.0%). Background: Stroke has been associated with rheumatoid arthritis (RA). Vascular physiology should be assessed in the preclinical vascular state. Objectives: We assessed RA patients and healthy controls by transcranial Doppler (TCD), carotid ultrasonography and brain MRI. We wished to determine preclinical pathophysiological changes in the cerebral vasculature. Methods: Altogether 63 female RA patients and 60 age-matched controls underwent TCD assessment of the medium cerebral (MCA), basilar and vertebral arteries. Pulsatility (PI), resistance (RI) indices and circulatory reserve capacity (CRC) were determined. The presence of carotid plaques and intima-media thickness (cIMT) were also determined. Intracerebral vascular lesions were investigated by brain MRI. RA subsets include MTX-and biologic-treated patients. Results: MCA PI and RI values at rest and after apnea are significantly increased in the total RA population vs controls. MCA PI (r) and RI (r) is also lower in biologic-treated patients. MCA CRC was also impaired and basilar artery PI was higher in RA. More RA patients had carotid plaques and had increased cIMT. Correlation analysis suggested multiple associations between right and left TCD
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Results:
The age-and gender distributions were similar across countries and drugs. Initiators of non-TNFi biologics were older than TNFI-initiators; the median age at start was the highest for rituximab. Out of a total of 8065 bio-initiations, 6% occurred in individuals with a history of cancer (2% with a cancer within 5 years, and 4% with a cancer more than 5 years before treatment start. Whereas there was little variation (around 5%) across TNFi initiators, the proportion of patients with a history of cancer at treatment start was higher among rituximab initiators, in part explained by age (Table) . There were only small variations across country (not shown).
Conclusions:
In Sweden, Finland and Iceland, one out of 20 biologics-initiators (and almost one out of five rituximab initiators) have a history of an invasive cancer, underscoring the need for more data on benefit/risks in this treatment context. The higher proportion in rituximab initiators is partly explained by differences in age at treatment start and reflects the preference for rituximab by clinicians for treatment of patients with history of cancer. 
